David König

527 total citations
26 papers, 247 citations indexed

About

David König is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, David König has authored 26 papers receiving a total of 247 indexed citations (citations by other indexed papers that have themselves been cited), including 18 papers in Oncology, 14 papers in Pulmonary and Respiratory Medicine and 6 papers in Molecular Biology. Recurrent topics in David König's work include Lung Cancer Treatments and Mutations (10 papers), Cancer Immunotherapy and Biomarkers (8 papers) and Lung Cancer Diagnosis and Treatment (5 papers). David König is often cited by papers focused on Lung Cancer Treatments and Mutations (10 papers), Cancer Immunotherapy and Biomarkers (8 papers) and Lung Cancer Diagnosis and Treatment (5 papers). David König collaborates with scholars based in Switzerland, Chile and Spain. David König's co-authors include Sacha I. Rothschild, Heinz Läubli, Spasenija Savic Prince, Alfred Zippelius, Laura C. Cappelli, Jarushka Naidoo, Till Wallrabenstein, Anne Bärenwaldt, Michal A. Stanczak and Michela Manni and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Annals of Oncology.

In The Last Decade

David König

19 papers receiving 244 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
David König Switzerland 7 145 95 83 65 34 26 247
Ahmed Bilal Khalid United States 3 145 1.0× 103 1.1× 70 0.8× 54 0.8× 29 0.9× 7 241
Xue‐Wu Wei China 8 185 1.3× 177 1.9× 69 0.8× 42 0.6× 54 1.6× 13 287
Dina Sakaeva Russia 9 165 1.1× 88 0.9× 96 1.2× 28 0.4× 48 1.4× 44 267
J. Infante United States 8 137 0.9× 66 0.7× 156 1.9× 30 0.5× 38 1.1× 17 273
Paz J. Vellanki United States 7 160 1.1× 115 1.2× 57 0.7× 41 0.6× 54 1.6× 13 254
Ya Zeng China 11 147 1.0× 156 1.6× 128 1.5× 64 1.0× 64 1.9× 25 342
Hengyu Lu United States 8 111 0.8× 55 0.6× 158 1.9× 52 0.8× 51 1.5× 11 269
Yuto Yasuda Japan 10 221 1.5× 172 1.8× 121 1.5× 59 0.9× 62 1.8× 35 346
Ying Cheng China 8 211 1.5× 102 1.1× 64 0.8× 31 0.5× 33 1.0× 48 269
Α. Kotsakis Greece 11 223 1.5× 147 1.5× 132 1.6× 65 1.0× 53 1.6× 23 338

Countries citing papers authored by David König

Since Specialization
Citations

This map shows the geographic impact of David König's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David König with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David König more than expected).

Fields of papers citing papers by David König

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by David König. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David König. The network helps show where David König may publish in the future.

Co-authorship network of co-authors of David König

This figure shows the co-authorship network connecting the top 25 collaborators of David König. A scholar is included among the top collaborators of David König based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with David König. David König is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Chijioke, Obinna, Ilaria Alborelli, Martin Zacharias, et al.. (2025). MTAP Expression by Immunohistochemistry: A Novel Biomarker in NSCLC. Journal of Thoracic Oncology. 21(1). 112–123.
2.
König, David, et al.. (2025). A risk score to predict postoperative complications in patients with resectable non-small cell lung cancer. Journal of Thoracic Disease. 17(3). 1520–1530.
3.
Blackham, A., Johannes Lorscheider, Jakob Passweg, et al.. (2025). Exacerbation of demyelinating polyneuropathy after adoptive cell therapy with tumour-infiltrating lymphocytes by metastatic melanoma. Swiss Medical Weekly. 155(8). 4221–4221.
4.
König, David & Heinz Läubli. (2025). Mechanisms of resistance to adoptive cell therapy with tumor-infiltrating lymphocytes. Expert Review of Clinical Immunology. 21(12). 1741–1754.
5.
Mangana, Johanna, Berna C. Özdemir, Heinz Läubli, et al.. (2024). Gender Differences in Melanoma Awareness, Diagnosis and Treatment: Patient-Reported Data from a Multicentre Survey in Switzerland. SHILAP Revista de lepidopterología. 4(6). e442–e442.
6.
Melero, Ignacio, Maria J. de Miguel, Guillermo de Velasco, et al.. (2024). Effects of neutralization of tumor-derived immunosuppressant GDF-15 on anti-PD-1 activity in anti-PD-(L)1 relapsed/refractory non-squamous NSCLC, urothelial, and hepatocellular cancer.. Journal of Clinical Oncology. 42(16_suppl). 2513–2513. 2 indexed citations
7.
Wallrabenstein, Till, David König, Laura C. Cappelli, et al.. (2024). Corticosteroid-resistant immune-related adverse events: a systematic review. Journal for ImmunoTherapy of Cancer. 12(1). e007409–e007409. 25 indexed citations
8.
Prince, Spasenija Savic, et al.. (2024). MTAP as an emerging biomarker in thoracic malignancies. Lung Cancer. 197. 107963–107963. 5 indexed citations
9.
Wallrabenstein, Till, et al.. (2023). Real-World Data of Combined Immunochemotherapy in Patients With Nonsquamous Advanced NSCLC. A Single-Center Retrospective Study. JTO Clinical and Research Reports. 4(5). 100509–100509. 2 indexed citations
10.
Joerger, Markus, Emiliano Calvo, Heinz Läubli, et al.. (2023). Phase 1 first-in-human dose-escalation study of ANV419 in patients with relapsed/refractory advanced solid tumors. Journal for ImmunoTherapy of Cancer. 11(11). e007784–e007784. 15 indexed citations
11.
Müller, Benjamin, Anne Bärenwaldt, Petra Herzig, et al.. (2023). Changes of peripheral T cell subsets in melanoma patients with immune-related adverse events. Frontiers in Immunology. 14. 1125111–1125111. 2 indexed citations
12.
Curioni‐Fontecedro, Alessandra, M. Frueh, David König, et al.. (2023). 1412P SAKK 17/18-ORIGIN trial: Efficacy and safety from a multicenter phase II trial of gemcitabine and atezolizumab in patients with advanced NSCLC progressing on immune checkpoint inhibitors. Annals of Oncology. 34. S807–S808. 1 indexed citations
13.
Calvo, Emiliano, Juanita Lopez, Dagmar Hess, et al.. (2023). 1031P ANV419, a selective IL-2Rβ/γ agonist in patients with relapsed/refractory advanced solid tumors. Annals of Oncology. 34. S626–S627. 1 indexed citations
14.
König, David, et al.. (2022). Larotrectinib Response in NTRK3 Fusion-Driven Diffuse High-Grade Glioma. Pharmacology. 107(7-8). 433–438. 14 indexed citations
15.
Wang, Jinyu, Michela Manni, Anne Bärenwaldt, et al.. (2022). Siglec Receptors Modulate Dendritic Cell Activation and Antigen Presentation to T Cells in Cancer. Frontiers in Cell and Developmental Biology. 10. 828916–828916. 33 indexed citations
16.
17.
König, David & Heinz Läubli. (2020). Mechanisms of Immune-Related Complications in Cancer Patients Treated with Immune Checkpoint Inhibitors. Pharmacology. 106(3-4). 123–136. 35 indexed citations
18.
König, David, Urs R. Meier, Bernd Klaeser, Spasenija Savic, & Miklos Pless. (2020). Successful Treatment of a Resistant Subclone in ALK-Rearranged NSCLC. Case Reports in Oncology. 13(2). 729–732. 1 indexed citations
19.
Schmid, Sabine, Laetitia Mauti, Alex Friedlaender, et al.. (2020). Outcomes with immune checkpoint inhibitors for relapsed small-cell lung cancer in a Swiss cohort. Cancer Immunology Immunotherapy. 69(8). 1605–1613. 6 indexed citations
20.
König, David. (1999). Hegel et la mystique germanique. L'Harmattan eBooks.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Ahmed Bilal Khalid Breakdown of academic impact, for papers by Xue‐Wu Wei Breakdown of academic impact, for papers by Dina Sakaeva Breakdown of academic impact, for papers by J. Infante Breakdown of academic impact, for papers by Paz J. Vellanki Breakdown of academic impact, for papers by Ya Zeng Breakdown of academic impact, for papers by Hengyu Lu Breakdown of academic impact, for papers by Yuto Yasuda Breakdown of academic impact, for papers by Ying Cheng Breakdown of academic impact, for papers by Α. Kotsakis
Rankless by CCL
2026